Advances in the application of mepolizumab in the treatment of FIP1L1-PDGFR<strong>α</strong>-negative hypereosinophilic syndrome

doi:10.3969/j.issn.1672-3384.2024.07.002

Advances in the application of mepolizumab in the treatment of FIP1L1-PDGFRα-negative hypereosinophilic syndrome

Jing MENG, Xuelan ZHANG, Jian ZHAO, Xiaomeng YE

Clinical Medication Journal ›› 2024, Vol. 22 ›› Issue (7) : 6-10.

PDF(394 KB)

Clinical Medication Journal ›› 2024, Vol. 22 ›› Issue (7) : 6-10. DOI: 10.3969/j.issn.1672-3384.2024.07.002

Review

Advances in the application of mepolizumab in the treatment of FIP1L1-PDGFRα-negative hypereosinophilic syndrome

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2024, 22(7): 6-10 https://doi.org/10.3969/j.issn.1672-3384.2024.07.002

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

Funding

RIGHTS & PERMISSIONS

PDF(394 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2024-01-25	2024-07-20
Issue Date
2024-08-08

Please choose a citation manager

Content to export